抗体に関する共同研究およびライセンシング契約：2019年～2025年

当レポートでは、世界の主要なバイオ医薬品企業が締結した抗体に関する契約について、包括的な理解とこれまでにない情報アクセスを提供します。

本レポートでは、企業がどのように、そしてなぜ抗体に関する契約を締結するのかについて、詳細な理解と分析を提供しています。これらの契約は一般的に複合的な構成を持ち、共同研究開発から始まり、その成果の商業化へと進展するケースが多く見られます。

収録対象には、共同研究、開発、ライセンス契約を含むさまざまなタイプの提携契約が含まれます。

本レポートには、2019年以降に発表された1,486件の抗体関連契約のリストが網羅されており、可能な限り契約金額などの財務条件も含まれています。さらに、各契約のオンライン記録へのリンクも掲載されており、実際に公開された契約の内容を参照できます。加えて、可能な場合には、企業やパートナー企業が米国証券取引委員会 (SEC) に提出した契約文書も記録に含まれています。

主な利点：

• 2019年以降の契約動向を把握
• 抗体に関する共同研究およびライセンス契約を閲覧
• ベンチマーク分析：取引の市場価値を特定
• 財務条件の詳細：一時金、マイルストン、ロイヤルティ
• 企業名 (A～Z)、契約タイプ、治療分野別の契約ディレクトリ
• 金額ベースでの主要な契約事例
• もっとも活発なディールメーカー
• 各契約における対象資産と契約条件を特定
• 契約文書にアクセス：契約構造に関する詳細な洞察
• デューデリジェンス：提案中の契約条件のパートナー企業にとっての妥当性の評価
• 数百時間分の調査時間を節約可能

契約書の分析を行うことで、以下の点についてデューデリジェンスを行うことができます：

• 正確にどのような権利が付与またはオプションとして与えられているか？
• 契約によって、パートナー企業に実際に何が付与されているか？
• どのような独占権が与えられているか？
• 契約の支払い構造はどうなっているか？
• 売上と支払いはどのように監査されるか？
• 契約期間 (有効期間) はどうなっているか？
• 契約の主要条項はどのように定義されているか？
• 知的財産権 (IPR) はどのように扱われ、誰が保有するか？
• 商業化の責任は誰が負うのか？
• 開発・供給・製造の責任は誰にあるか？
• 秘密保持および成果の公開はどのように管理されるか？
• 紛争はどのように解決することになっているか？
• どのような条件下で契約が終了できるか？
• 企業の所有権が変更された場合、契約はどうなるか？
• サブライセンスや下請けに関する条項はどう合意されているか？
• 会社側が必ず盛り込む「雛型条項」は何か？
• 契約相手や契約タイプによって異なる「雛型条項」は何か？
• 契約法上、会社が準拠法として要求する法域 (裁判管轄) はどこか？

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 抗体契約の動向

• 年次別の抗体契約件数
• もっとも活発な契約締結企業
• 抗体契約：契約タイプ別
• 抗体契約：治療分野別
• 抗体契約：業界別
• 抗体契約の取引条件

第3章 主要な抗体契約

• 主要抗体契約：契約金額別

第4章 もっとも活発な抗体契約締結企業

• もっとも活発な抗体契約締結企業
• もっとも活発な抗体契約締結企業プロファイル

第5章 抗体契約の取引ディレクトリ

• 抗体契約の取引ディレクトリ

第6章 抗体契約：技術タイプ別

• 契約ディレクトリ
• 契約ディレクトリ- 企業別 (A-Z)
• 契約ディレクトリ- 契約タイプ別
• 契約ディレクトリ- 治療分野別
• 契約タイプの定義
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• Current Partneringからの最近のレポートタイトル

Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibody deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1486 antibody deals announced since 2019 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

• Trends in antibody dealmaking in the biopharma industry
• Directory of antibody deal records covering pharmaceutical and biotechnology
• The leading antibody deals by value
• Most active antibody licensing dealmakers
• Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

• 2.1. Introduction
• 2.2. Antibody deals over the years
• 2.3. Most active antibody dealmakers
• 2.4. Antibody deals by deal type
• 2.5. Antibody deals by therapy area
• 2.6. Antibody deals by industry sector
• 2.7. Deal terms for antibody deals
  • 2.7.1 Antibody deals headline values
  • 2.7.2 Antibody deal upfront payments
  • 2.7.3 Antibody deal milestone payments
  • 2.7.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

• 3.1. Introduction
• 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

• 4.1. Introduction
• 4.2. Most active antibody dealmakers
• 4.3. Most active antibody deals company profiles

Chapter 5 - Antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

• Deal directory
• Deal directory - Antibody deals by company A-Z
• Deal directory - Antibody deals by deal type
• Deal directory - Antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Antibody deals since 2019
• Figure 2: Active antibody dealmaking activity - 2019 - 2025
• Figure 3: Antibody deals by deal type since 2019
• Figure 4: Antibody deals by therapy area since 2019
• Figure 5: Antibody deals by industry sector since 2019
• Figure 6: Antibody deals with a headline value
• Figure 7: Antibody deals with an upfront value
• Figure 8: Antibody deals with a milestone value
• Figure 9: Antibody deals with a royalty rate value
• Figure 10: Top antibody deals by value since 2019
• Figure 11: Most active antibody dealmakers 2019 - 2025
• Figure 12: Antibody deals by technology type since 2019